Not registered yet? Please contact our project assistant Dennis Cleff . This area is only for members of the research consortium.
UNIBO

Alma Mater Studiorum - Universita di Bologna

Department of Medical and Surgical, Operative Unit of Medical Semeiotics
via Massarenti, 9
40138 Bologna
ITALY
Visit website
Visit website

Team Leader

Prof. Dr. Paolo Caraceni

Head of Unit, Full Professor of Internal Medicine
Phone: +39 051 214 2919
Send message

Team Staff

Dr. Stefania Lorenzini

Senior Hospital Specialist & Consultant
Phone: +39 051 214 2925
Send message

Dr. Giacomo Zaccherini

Researcher and Assistant Professor
Phone: +39 051 214 2918
Send message

Dr. Maurizio Baldassarre

Hospital Researcher
Phone: +39 051 214 2918
Send message

Dr. Greta Tedesco

Post-Doctoral Fellow & Study Coordinator
Phone: +39 051 214 2918
Send message

Dr. Enrico Pompili

Research Fellow & PhD Student
Phone: +39 051 214 2918
Send message

Dr. Giulia Iannone

Resident & Junior Hospital Physician
Phone: +39 051 214 2918
Send message

Institute Presentation

The University of Bologna (UNIBO), created in the year 1088, is recognized ad the oldest university in the western world, and one the largest in Italy (with more than 85 000 enrolled students per year). The Unit of Semeiotica Medica is part of the UNIBO Department of Medical and Surgical Sciences within the University Hospital “Azienda Ospedaliero Universitaria Sant’Orsola – Malpighi” Polyclinic (AOSP). The main tasks of this structure are the management and prevention of complications of cirrhosis while the research activity of the unit is devoted to preclinical, translational, and clinical research in the field of complications of cirrhosis to optimize management and prevention of decompensation and acute-on-chronic liver failure (ACLF).

Within the DECISION project, UNIBO is the leader of WP5. In particular, UNIBO will contribute to the selection of the combinatorial therapy derived from the preclinical validation, and be responsible for the design, conduction, and coordination of the clinical trial in close collaboration with EF CLIF. Moreover, the PI Prof. Caraceni will lead the Clinical Trial Management Committee (CTMC) with the aim to coordinate and supervise the clinical trial.